According to Dr. Robert Schock, VP of R&D at LRS, "Laboratory studies have predicted that rapid, early cooling would be effective in reducing brain injuries caused by ischemic strokes, while slow, ...

The growth of the acute ischemic stroke market is expected to be driven primarily by increased awareness of symptoms, advances in acute stroke care, and a robust pipeline of potential candidates such ...

Advances in cancer treatment mean that more people than ever are surviving the disease. However, some of the most effective ...

A retrospective study shows a synergistic interaction between Parkinson disease and stroke, leading to increased long-term mortality risk.

Asundexian reduced ischemic stroke risk without increasing major bleeding in the OCEANIC-STROKE study, meeting primary efficacy and safety endpoints. The study included 12,327 patients with acute ...

Patients receiving complex PCI face increased risk of all-cause mortality and major bleeding, particularly those with a high bleeding risk profile.

Cardiovascular disease remains the leading cause of mortality worldwide, necessitating deeper insights into its molecular ...

Stroke and transient ischemic attack (TIA) share similar risk factors and methods of evaluation and secondary prevention. As neurological symptoms resolve after TIA, however, there has been a widely ...

A massive report on the world’s health highlights the impact cardiovascular disease continues to have in all regions of the globe, with ischemic heart disease accounting for 10 million deaths and ...

Bayer recently reported that its oral factor XIa inhibitor asundexian reduced the risk of recurrent ischemic stroke in patient ...

Each year in the United States 200,000–500,00bstract: 500,000 people have a transient ischemic attack (TIA). These episodes of brief neurologic deficits were thought to be fairly benign, but this view ...